BioPharma Resources

Drug Trial Radar · NCT05947890

Evaluating the Safety and Immunogenicity of MTBVAC

A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of MTBVAC

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

276

Planned (sponsor's estimate)

Start

Jan 30, 2024

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
HIV Vaccine Trials NetworkResearch network
Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Biofabri, S.L; Fred Hutchinson Cancer Center
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of MTBVAC in adolescents and adults living with and without HIV in South Africa

Conditions

  • HIV I Infection
  • Tuberculosis

Interventions

  • MTBVACBiological

    The MTBVAC vaccine is a freeze-dried lyophilized pellet containing live attenuated strain MTBVAC01 derived from Mycobacterium tuberculosis (M.tb). Excipients include sucrose and sodium glutamate.

  • BCGBiological

    The active substance in BCG vaccine is a freeze-dried powder containing live attenuated Mycobacterium bovis BCG, Danish strain 1331 and sodium glutamate as a stabilizer. The powder is white and crystalline and may be difficult to see due to the small amount contained in each vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of unsolicited adverse eventsTime frame: Through study week 48
  2. Number of solicited adverse eventsTime frame: Through study week 16
  3. Number of Grade 3 or higher adverse eventsTime frame: Through study week 48
  4. Number of serious adverse eventsTime frame: Through study week 48
  5. Frequency and response of MTBVAC-reactive CD4+ cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks 4
  6. Frequency and response of MTBVAC-reactive CD4+ cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks10
  7. Frequency and response of MTBVAC-reactive CD8+ T cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks 4
  8. Frequency and response of MTBVAC-reactive CD8+ T cells expressing Th1 and/or Th17 cytokinesTime frame: At baseline and study weeks10

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Cape Town - Khayelitsha

    Cape Town, South Africa · Recruiting

  • Durban - Chatsworth

    Chatsworth, South Africa · Recruiting

  • Durban eThekwini

    Durban, South Africa · Terminated

  • Durban - Isipingo

    Isipingo, South Africa · Recruiting

  • Klerksdorp

    Klerksdorp, South Africa · Recruiting

  • Ladysmith

    Ladysmith, South Africa · Recruiting

  • Rustenburg CRS

    Rustenburg, South Africa · Terminated

  • Soshanguve

    Soshanguve, South Africa · Terminated

  • Soweto - Gauteng

    Johannesburg, Gauteng, South Africa · Terminated

  • Johannesburg - CHRU

    Westdene, Gauteng, South Africa · Recruiting

  • Durban - Botha's Hill CRS

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • Durban - Wentworth

    Durban, KwaZulu-Natal, South Africa · Terminated

  • Cape Town - UCTLI

    Cape Town, Western Cape, South Africa · Recruiting

  • Cape Town - Emavundleni

    Cape Town, Western Cape, South Africa · Terminated

  • Cape Town - Groote Schuur

    Cape Town, Western Cape, South Africa · Recruiting

  • Worcester - SATVI

    Worcester, Western Cape, South Africa · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.